Stoke director granted 17,786 stock options
Stoke Therapeutics director Jennifer Burstein received a grant of stock options covering 17,786 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Stoke Therapeutics director Jennifer Burstein received a grant of stock options covering 17,786 shares of common stock. These options have an exercise price of $29.46 per share and expire on June 2, 2036. The filing shows she holds 17,786 derivative securities following this grant. According to the vesting terms, the option will vest in full on the earlier of June 3, 2027 or the date of Stoke Therapeutics’ next annual stockholder meeting, provided she continues serving the company through that vesting date.
Insider Trade Summary
Grant/Award: 17,786 shares
Grant/Award
1 txn
Insider
Burstein Jennifer
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Director Stock Option (Right to Buy) | 17,786 | $0.00 | $0.00 |
Holdings After Transaction:
Director Stock Option (Right to Buy) — 17,786 contracts (Direct)
Footnotes (1)
- F1. The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date.
Key Figures
Option grant size: 17,786 options
Exercise price: $29.46 per share
Underlying shares: 17,786 shares
+3 more
6 metrics
Option grant size
17,786 options
Director stock option grant to Jennifer Burstein
Exercise price
$29.46 per share
Exercise price for granted options
Underlying shares
17,786 shares
Common stock underlying the options
Post-grant derivative holdings
17,786 options
Total derivative securities held after transaction
Option expiration
June 2, 2036
Expiration date of the director stock option
Vesting date trigger
Earlier of June 3, 2027 or next annual meeting
Full-vesting condition subject to continued service
Key Terms
Director Stock Option, exercise price, expiration date, vesting, +1 more
5 terms
Director Stock Option financial
"security_title: Director Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 29.4600"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date regulatory
"expiration_date: 2036-06-02T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"The option shall vest in full on the earlier of"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Jennifer Burstein report in this Stoke Therapeutics (STOK) Form 4?
Jennifer Burstein reported receiving a stock option grant for 17,786 shares of Stoke Therapeutics common stock at an exercise price of $29.46 per share, recorded as a derivative acquisition rather than an open-market purchase.
Is the Form 4 transaction for Stoke Therapeutics (STOK) an open-market buy or a grant?
The Form 4 shows a grant/award acquisition, not an open-market purchase. Burstein received 17,786 director stock options at a $29.46 exercise price, classified under transaction code “A” for grants or awards.
When do Jennifer Burstein’s new Stoke Therapeutics (STOK) options vest?
The options vest in full on the earlier of June 3, 2027 or the next annual stockholder meeting. Vesting is conditional on her continued service to Stoke Therapeutics through that vesting date.
What is the size of the option position reported for Stoke Therapeutics (STOK)?
After the transaction, Jennifer Burstein holds 17,786 director stock options as reported in the Form 4. Each option relates to one share of Stoke Therapeutics common stock and carries an exercise price of $29.46 per share.
What is the expiration date of the Stoke Therapeutics (STOK) options granted to Jennifer Burstein?
The director stock options granted to Jennifer Burstein expire on June 2, 2036. She may exercise them at an exercise price of $29.46 per share, subject to vesting and continued service conditions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates